Benjamin J Solomon
Overview
Explore the profile of Benjamin J Solomon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
107
Citations
11561
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Gautschi O, Park K, Solomon B, Tomasini P, Loong H, De Braud F, et al.
J Clin Oncol
. 2025 Feb;
:JCO2402076.
PMID: 39983053
LIBRETTO-001 (ClinicalTrials.gov identifier: NCT03157128) is a registrational phase I/II, single-arm, open-label trial of selpercatinib in RET-dependent cancers. With 19 months of additional follow-up, we report the final efficacy and safety...
2.
3.
Lee C, Liao B, Subramaniam S, Chiu C, Mersiades A, Ho C, et al.
JTO Clin Res Rep
. 2025 Jan;
6(2):100771.
PMID: 39877028
Introduction: -mutant NSCLC is associated with low mutation burden and low levels of PD-L1 expression. We conducted a phase 2 trial to determine the efficacy of durvalumab, tremelimumab, and platinum-pemetrexed...
4.
Ou S, Solomon B, Besse B, Bearz A, Lin C, Chiari R, et al.
J Thorac Oncol
. 2024 Nov;
PMID: 39581380
Introduction: Lorlatinib is a potent, brain-penetrant, third-generation inhibitor of anaplastic lymphoma kinase (ALK) and ROS1 tyrosine kinases with broad coverage of ALK resistance mutations. We present the overall survival (OS)...
5.
Cheung B, Mittra R, Murray J, Wang Q, Seneviratne J, Raipuria M, et al.
Commun Biol
. 2024 Oct;
7(1):1322.
PMID: 39402275
MYCN amplification predicts poor prognosis in childhood neuroblastoma. To identify MYCN oncogenic signal dependencies we performed N-ethyl-N-nitrosourea (ENU) mutagenesis on the germline of neuroblastoma-prone TH-MYCN transgenic mice to generate founders...
6.
Solomon B, Liu G, Felip E, Mok T, Soo R, Mazieres J, et al.
Future Oncol
. 2024 Oct;
20(40):3377-3387.
PMID: 39360949
What Is This Study About?: This is a summary of the results of an ongoing study called CROWN. In the CROWN study, researchers looked at the effects of two medicines...
7.
Itchins M, Liang S, Brown C, Barnes T, Marx G, Chin V, et al.
JTO Clin Res Rep
. 2024 Sep;
5(9):100703.
PMID: 39309618
Introduction: ALK-positive lung cancers represent a molecularly diverse disease. With drug exposure, driving selection pressure, and resistance pathways, disease relapse will emerge. There is compelling rationale to investigate novel treatment...
8.
Smith K, OHaire S, Markman B, Gan H, OByrne K, Millward M, et al.
JCO Precis Oncol
. 2024 Aug;
8:e2300247.
PMID: 39208376
Purpose: Despite increasing evidence of benefit supporting complex genomic sequencing (CGS) in personalizing cancer therapy, its widespread uptake remains limited. Methods: This mixed-methods, prospective cross-institutional demonstration study was designed to...
9.
Solomon B, Dagogo-Jack I, Lee S, Boyer M, Ramalingam S, Carcereny E, et al.
JTO Clin Res Rep
. 2024 Jul;
5(7):100685.
PMID: 39034968
Introduction: The JAVELIN Lung 101 phase 1b/2 trial evaluated avelumab (immune checkpoint inhibitor) combined with lorlatinib or crizotinib (tyrosine kinase inhibitors) in -positive or -negative advanced NSCLC, respectively. Methods: Starting...
10.
Felip E, Metro G, Soo R, Wolf J, Solomon B, Tan D, et al.
Eur J Cancer
. 2024 Jul;
208:114182.
PMID: 38986421
Purpose: This phase 1b/2 trial evaluated the efficacy and safety of capmatinib plus nazartinib in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC). Methods: In phase 1b, patients with...